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Ethanol Sclerotherapy for the
Management of Craniofacial Venous
Malformations: the Interim Results
Objective: We wanted to evaluate the safety and feasibility of ethanol scle-
rotherapy for treating craniofacial venous malformations (CVMs).
Materials and Methods: From May 1998 to April 2007, 87 patients (40 men
and 47 women; age range, 2-68 years) with CVMs underwent staged ethanol
sclerotherapy (range, 1-21 sessions; median number of sessions, 2) by the direct
puncture technique. Clinical follow up (range, 0-120 months; mean follow up, 35
months; median follow up, 28 months) was performed for all the patients.
Therapeutic outcomes were established by evaluating the clinical outcome of the
signs and symptoms in all patients, as well as the degree of devascularization,
which was determined on the follow-up imaging, in 71 patients.
Results: A total of 305 procedures with the use of ethanol were performed in
87 patients. Follow-up imaging studies were performed for 71 of 87 patients.
Twenty-three (32%) of the 71 patients showed excellent outcomes, 37 patients
(52%) showed good outcomes and 11 patients (16%) showed poor outcomes.
Ethanol sclerotherapy was considered effective for 60 patients. All the minor
complications such as bulla (n = 5) healed with only wound dressing and obser-
vation. Any major complication such as skin necrosis did not develop.
Conclusion: Percutaneous ethanol sclerotherapy is an effective, safe treat-
ment for CVMs.
enous malformations (VMs) are the most common vascular malforma-
tions and they consist of dysplastic venous channels. These lesions are
present at birth and they grow proportionately with age (1-4). VMs also
cause various clinical presentations from a simple birthmark to a life-threatening
condition, including skeletal anomalies or an intravascular coagulopathy (5-7). VMs
can involve any location, including the head and neck area. Craniofacial VMs (CVMs)
involve multiple anatomical spaces and significant neuromuscular structures (8).
Surgery in the head and neck area for CVMs is difficult to perform and it usually leads
to nerve damage, massive bleeding and/or deformity, and it has a high recurrence rate
and high morbidity (8). Therefore, CVMs have been treated with various treatment
techniques as the primary or preoperative therapy. Sclerotherapy for CVMs has an
advantage of producing no external scarring and it causes few complications compared
with surgical treatment. Ethanol has been the most commonly used agent for percuta-
neous sclerotherapy for the treatment of congenital vascular lesions (5, 8-11).
However, the previous studies have generally included only a small number of
patients with CVMs (8, 12). The purpose of this study was to describe the safety and
the feasibility of ethanol sclerotherapy for the treatment of a relatively large series of
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VCVMs and to assess the method’s clinical efficacy.
MATERIALS AND METHODS
Patient Population and Evaluation
From May 1998 to April 2007, a series of 87 consecutive
patients (40 men and 47 women, mean age, 17.5 years;
age range, 2-68 years) at our hospital and who had CVMs
were treated with percutaneous ethanol sclerotherapy.
Approval from the institutional review board was not
needed for reviewing their medical records and the
radiological images for research purposes at our institute.
We retrospectively reviewed the clinical and radiological
findings. For all the cases, written informed consent was
obtained from the patients or their parents before the
procedures. Diagnosing the CVMs was based on the
clinical and gross anatomic findings and the radiological
examinations of all the patients. The clinical criterion for
the diagnosis of CVMs was an early presentation, and
especially at birth, of the presenting features of a lesion
with slow and steady or progressive growth with age. A
confirmed radiological diagnosis was made by regurgita-
tion of blood on direct puncture venography in all the
patients. We also examined the masses that had wide
venous pools, as established on magnetic resonance
imaging (MRI) (n = 85), computed tomography (CT) (n =
23) and whole body blood pool scintigram (WBBPS) (n =
45). We performed MRI for evaluating the extent of
disease, and MRI was helpful for making the diagnosis of
VM, especially when a phlebolith was present in the lesion.
Physical examinations were also performed to evaluate the
lesions. The imaging studies, which were mainly comprised
of MR imaging and WBBPS, were used to obtain the
baseline data. Seventy-one of 87 patients underwent MR
imaging or WBBPS after sclerotherapy. MR imaging was
performed with a 1.5-T unit (Signa; GE Medical Systems,
Milwaukee, WI). The MR imaging protocol included the
axial, sagittal and coronal imaging with the fat saturated
T2-weighted sequences, the axial gradient echo and T1-
weighted images and/or the contrast enhanced T1-
weighted images.
Sclerotherapy Procedure
After reviewing the imaging studies, we performed direct
puncture venography to evaluate the size, location and
anatomy of the lesions and the hemodynamics, and we
determined the possible sites of these lesions in all the
patients. The lesions were directly punctured using 23-
gauge needles with all the patients under general anesthe-
sia. When venous reflux was established, contrast material
was then injected manually to perform digital subtraction
angiography for evaluating the extent and volume of the
lesions and for draining the venous system. However, the
extent and volume of the lesions were not evaluated
sufficiently in several patients because the contrast
material did not fill the large, nondependent areas of the
VMs, which consisted of wide venous spaces or partially
collapsed lesions. The ethanol used in sclerotherapy was
usually kept in a refrigerator. After confirming the CVM
via direct puncture venography, we used pure or diluted
ethanol (i.e., 2 ml of 50% ethanol means 1 ml of ethanol
mixed with 1 ml of contrast media). The ethanol was
injected together with a simultaneous fluoroscopic “road
map” to ensure intralesional administration and to prevent
unwanted extravasation into the surrounding normal tissue
or draining veins, or to prevent massive vascular penetra-
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Fig. 1. 5-year-old-girl with venous malformation in right cheek.
A. Coronal T2 weighted image shows venous malformation (arrow) in right cheek.
B. Direct puncture venography shows opacification of venous malformation.
C. Coronal T2 weighted image obtained after two sessions of sclerotherapy with ethanol reveals significant shrinkage of venous malfor-
mation (arrow).
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tion. In the cases of using pure ethanol, we performed the
procedures by dividing the permitted ethanol dose into
small amounts, which were less than the amount of
contrast media used, for preventing extravasation. Ethanol
injection was stopped when the venous pools were
sufficiently filled according to the enlargement of the
lesions or when resistance to the injection was encountered
or opacification of the venous drainage was seen. The
volume of ethanol injection was calculated based on the
size and location of the VMs and the weight of the patient.
We calculated the size of the VMs as based on the contrast
media that was used for the direct puncture venography. A
maximum ethanol volume of 1 ml/kg was injected in a
single session. However, the actual amount of ethanol we
used was less than half of the maximum amount permitted
for most patients. Pure (99.9%) ethanol was used in 166
sessions of the total 305 sessions of ethanol sclerotherapy,
and diluted ethanol (50-90%) with nonionic contrast
medium (iobitridol, Xenetix 300; Guerbet, France) was
used in 139 sessions of the total ethanol sclerotherapy
sessions. We used pure ethanol as much as possible
because pure ethanol is more effective than diluted
ethanol, but diluted ethanol was used in the lesions
adjacent to skin to prevent skin necrosis. The amount of
injected alcohol ranged from 1 ml (pure ethanol) to 76 ml
(58 ml of pure alcohol and 18 ml of 90% diluted alcohol).
After the ethanol injections, we waited for 10 minutes and
the stasis of ethanol in the lesions was reconfirmed at the
end of the procedure by a further injection of contrast
medium. If the lesions showed high flow or prominent
venous drainage, then manual compression of the outflow
was performed before injection of ethanol. The patients
were carefully observed during these procedures and for at
least 24 hours after the procedures to detect complications.
Evaluation and Follow up
Clinical follow up was possible for all 87 patients and the
duration of the follow-up period ranged from 10 days to
120 months (mean: 35 months). The effectiveness of
sclerotherapy was assessed based on the clinical findings
and the radiological findings of the follow-up MR imaging
or WBBPS. Two radiologists who worked in consensus
analyzed the therapeutic responses to ethanol sclerother-
apy by comparing the size of the VMs between the
baseline MR imaging and the follow-up MR imaging. The
effectiveness of percutaneous sclerotherapy was also
assessed by quantitatively measuring the reduction of the
radioisotope count over the designated lesion between the
baseline WBBPS and the follow-up WBBPS. Excellent was
defined as clinical obliteration of the signs and symptoms
with over 75% reduction of uptake on the WBBPS or near
complete obliteration of the VM on the MR imaging. Good
was defined as complete or partial resolution of the signs
and symptoms with a 25-75% reduction of uptake on the
WBBPS or a 25-75% size decrement on the MR imaging.
Poor was defined as partial resolution or no change of the
signs or symptoms with less than a 25% reduction of
uptake on the WBBPS or less than a 25% size decrement
on MRI.
Periprocedural Complications
Complications were classified into major and minor
complications according to the Society of Cardiovascular
and Interventional Radiology (SCVIR) reporting standards.
Fig. 2. 5-year-old-boy with venous malformation in right temporalis muscle.
A. Fat suppression axial T2 weighted image demonstrates presence of venous malformation (arrow) with phlebolithes (arrowheads) in
right temporalis muscle.
B. Direct puncture venography shows opacification of venous malformation.
C. Fat suppression axial T2 weighted image obtained after one session of sclerotherapy shows significant shrinkage of venous malfor-
mation (arrow) in right temporalis muscle. 
ABCThe major complications included death, systemic
embolization of the sclerosant, renal toxicity, hepatic
toxicity, nerve damage, overlying skin injury and trismus.
The minor complications included any nonpermanent
adverse sequela such as indurations, swelling and pain that
required nominal therapy or no therapy. Physical and
neurological examinations were performed before and
after sclerotherapy to assess the complications. Laboratory
examinations were considered for the cases with signs or
symptoms related to renal or hepatic toxicity.
RESULTS
Details of the Patients
All the patients reported cosmetic concerns at presenta-
tion. Before undergoing sclerotherapy in our hospital, 26
patients had undergone surgical excision or sclerotherapy
at another hospital. One of them had also undergone
previous partial excision at our hospital.
Therapeutic Outcomes
Among the total 87 patients, 45 patients had diffuse or
multispace CVMs and the other 42 patients had localized
CVMs. The number of required procedures varied from
patient to patient, depending on the size and behavior of
the lesions. The total number of procedures was 213
(range, 1-21; mean number of sessions, 4.7) for the
patients with diffuse or multispace CVMs and 92 (range, 1-
8; mean number of sessions, 2.2) for the patients with
localized CVMs. A total of 305 ethanol sclerotherapy
sessions (range, 1-21; mean number of sessions, 3.5) were
performed for the 87 patients. Two or more procedures
were performed for 67 patients. After or during a course of
sclerotherapy, seven of 87 patients underwent plastic
surgery for cosmetic deformity. Follow-up imaging studies
were performed for 71 of 87 patients. Twenty three
(32.4%) of the 71 patients showed an excellent outcome,
37 patients (52.1%) showed a good outcome (Figs. 1-4)
and 11 patients (15.5%) showed a poor outcome (Fig. 5).
Ethanol sclerotherapy was considered effective for 60
(84.5%) of the 71 patients. The responses after percuta-
neous ethanol sclerotherapy are summarized in Table 1.
Complications
There were no major complications such as skin necrosis.
Two patients experienced transient oxygen desaturation,
which was probably due to pulmonary hypertension,
immediately after the injection of ethanol. However, the
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Fig. 3. 16-year-old-man with venous malformation involving tongue, lower face and left parapharyngeal space.
A. Clinical appearance of soft tissue mass that is located in patient’s left cheek.
B. Direct puncture venography shows opacification of venous malformation.
C. Near-complete shrinkage of venous malformation was obtained with three sessions of sclerotherapy.
ABC
Table 1. Responses after Percutaneous Ethanol
Sclerotherapy
Response Localized
Diffuse or 
Number (%)
Multispace
Excellent 19 (26.8%) 4 (5.6%) 23 (32.4%)
Good 12 (16.9%) 25 (35.2%) 37 (52.1%)
Poor 1 (1.4%) 10 (14.1%) 11 (15.5%)
Total 32 39 71oxygen saturation immediately recovered. One patient
with a tongue VM experienced transient reduction of the
sensation of the tongue and the other patient with a cheek
VM experienced transient facial nerve palsy (Table 2). For
all the patients, there was induration and swelling of the
lesions immediately after injection of the ethanol. Most
patients reported pain at the areas of the lesions, which
was effectively controlled by intravenous or intramuscular
analgesics. There were no major complications related to
the procedures, such as embolism of ethanol into the
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Fig. 4. 36-year-old woman with venous malformation in left cheek.
A. Fat suppression axial T2 weighted image demonstrates presence of venous malformation (arrow) in left cheek.
B. Direct puncture venography shows opacification of venous malformation.
C. Fat suppression axial T2 weighted image obtained after two sessions of sclerotherapy shows 50% shrinkage of venous malformation
(arrow) in left cheek.
ABC
Fig. 5. 15-year-old man with venous malformation involving tongue, lower face and left parapharyngeal space.
A. Fat suppression axial T2 weighted image demonstrates presence of venous malformation (arrows) involving tongue, lower face and
left parapharyngeal space.
B. Direct puncture venography shows opacification of venous malformation.
C. Fat suppression axial T2 weighted image obtained after nine sessions of sclerotherapy shows no significant change of venous malfor-
mation involving tongue and lower face.
ABC
Table 2. Complications after Percutaneous Ethanol
Sclerotherapy
Complication Number (%)
Skin necrosis 0/00 (0)
Respiratory difficulty 2/87 (2.3%) 
(Saturation decrement)
Tongue dullness 1/87 (1.15%)
Transient facial nerve palsy 1/87 (1.15%)
Total  4/87 (4.6%)systemic circulation, injury of the skin overlying the lesion
or nerve injury. No patients reported signs or symptoms
related to renal or hepatic toxicity.
DISCUSSION
Depending on the predominantly involved vasculature,
congenital vascular malformations are classified as arterial,
capillary, lymphatic, venous or combined (1, 12-16).
Histologically, VMs consist of thin-walled channels that are
lined with a single layer of endothelium, which is deficient
in smooth muscle (1, 4). VMs consist of dilated venous
spaces with very slow blood flow histologically and these
dilated venous spaces are uncommonly seen on arteriogra-
phy, so conventional or direct puncture venography is
necessary to visualize the lesions and define their extent
(17, 18). The diagnosis of VMs is based on a careful history
taking and the clinical examination. The lesions may be
localized or they can involve extensive areas of the body.
The symptoms vary depending on the location and size of
the lesions and even small VMs can cause severe pain.
Craniofacial VMs may be become more engorged during
the Valsalva maneuver or they are dependent on position-
ing (16). Most patients with craniofacial VMs have
concerns for cosmetic considerations more than for
functional difficulties. Besides sclerotherapy and surgery,
VMs have been treated by a variety of techniques, includ-
ing irradiation, electrocoagulation, cryotherapy, intravas-
cular magnesium or the use of copper needles, lasers and
compression. All these techniques have their particular
indications and limitations. Surgical excision is useful only
for the localized and limited lesions. Aggressive excision
can lead to significant loss of motor function, cosmetic
problems, nerve damage or massive bleeding in patients
with extensive involvement because of the complicated
anatomy of the face and neck.
Sclerotherapy has several advantages, including no
external scarring, and it incurs few complications as
compared with surgical treatment. There are various
choices of agents to use for sclerotherapy: 5% sodium
morrhuate, sodium tetradecyl sulphate (Sotadecol),
ethanolamine oleate, OK432, bleomycin, ethanol and
hypertonic saline, alone or in various combinations, have
all been used (1, 12, 13, 18-25).
There is no ideal vaso-occlusive substance applicable to
all VMs. Among the different sclerosing agents, ethanol is
the most popular and potent and it shows the lowest rate
of recurrent malformation. Ethanol is considered the most
reliable of all of the sclerosing agents (5, 12, 16, 26).
However, ethanol sclerotherapy requires general anesthe-
sia because the procedure is very painful (21). Direct
percutaneous puncture venography is required to measure
the lesion volume and to confirm the involvement of
multiple compartments. 
In our study, we used 50-90% ethanol mixed with
contrast media, as well as pure ethanol. The radiopacity of
the contrast media mixed with ethanol for percutaneous
sclerotherapy or direct puncture venography is beneficial
for monitoring procedures and the contrast media shows
the distribution of the ethanol injected into the lesions (18,
27). After injection, ethanol sclerotherapy requires
extended contact with the endothelial lining to cause
disruption of the endothelium, intense inflammatory
reactions and blood coagulation (1, 4, 16, 21).
Sclerotherapy is most successful when the vascular spaces
are small or when the blood flow is slow, and the possibil-
ity of dilution must be considered in the large vascular
spaces or that dispersion can happen due to fast blood
flow. To achieve the necessary result and to minimize the
flow of ethanol into the normal venous drainage structures,
several techniques have been used, including manual
compression, the use of rubber bands to compress the
forehead and chin to occlude facial venous return or
mechanical occlusion of the draining vein (8). In our study,
manual compression was used for some of the patients.
Because an excessively forceful injection into the lesion
causes ethanol to flood into the systemic circulation and
this can increase the development of complications, the
injection rate and amount must be carefully controlled
under fluoroscopic guidance. In most patients, swelling and
hardness of the VMs were seen just after the injection of
ethanol. After the procedure, the pain due to the
expansion of blood pools was effectively treated with
intravenous or intramuscular analgesics. The major compli-
cations of sclerotherapy include skin necrosis, peripheral
nerve palsies and hypotensive crisis, as well as fatalities
such as cardiac arrest and pulmonary emboli (22, 24, 28-
33). In our study, none of the patients experienced skin
necrosis or permanent facial nerve palsy, except for two
cases with tongue dullness in one patient with a tongue VM
and transient facial nerve palsy in one patient with a cheek
VM. For prevention of complications such as skin necrosis,
we used diluted ethanol in the lesion adjacent to skin. Two
patients experienced transient pulmonary hypertension in
our study. To avoid a catastrophic situation such as acute
pulmonary hypertension with cardio-pulmonary collapse,
it is suggested to inject the ethanol slowly and combine this
with rubber band compression and not to exceed a level of
1 ml ethanol/kg of body weight, along with monitoring the
pulmonary artery pressure (12, 21, 34, 35). For prevention
of pulmonary hypertension during the procedures in our
study, nitroglycerin (0.5-1 μ g/kg/min) was administered
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anesthesia. The volume of ethanol to be injected is
determined from the percutaneous study with injecting
intralesional contrast medium. The reported complication
rates for ethanol sclerotherapy have ranged from 7.5 to
26.7% (5, 13, 24, 34, 35), and the complication rate was
4.6% in our study (Table 2) and there were no major
complications such as skin necrosis or permanent nerve
injury. Although percutaneous ethanol sclerotherapy was
considered effective in 60 of the 71 patients with follow-up
images, all the patients experienced symptomatic or
cosmetic improvement. This success rate (84.5%) is
comparable to those (60-95%) described in the previous
reports in which VMs were treated by percutaneous
sclerotherapy with the same agent we used or with other
liquid agents, but with the use of a similar technique (11,
18, 22-25). 
The following feature was noted for those CVMs with a
poor outcome. Ten (91%) of the 11 patients with a poor
outcome had diffuse or multispace CVMs, the targeted
lesions were limited to the site of percutaneous sclerother-
apy and the targeted lesions were matched to the needs of
the patient (Table 1). Most of all, we tried to reduce the
cosmetic problems rather than to reduce the functional
problems because almost all the patients had cosmetic
problems and they wanted cosmetic improvement. Even
though the degree of devascularization of CVMs in the
patients with a poor outcome was less than 25%, the
clinical satisfaction of the patients was more than a good
outcome. Several sessions of ethanol sclerotherapy are
necessary for very large VMs because recanalization can
occur. Further, several sessions of ethanol sclerotherapy
can help to reduce the risk of major morbidity due to the
ethanol injection (1, 5), and so two or more procedures
were performed in 67 patients in our study. However, the
use of percutaneous ethanol sclerotherapy may be limited
in inaccessible lesions due to the lack of a proper vein for
direct puncture, in lesions with venous outflow connected
to the deep vein system and in lesions surrounding a nerve
(5, 11).
There are limitations in our study. As not all the patients
with ethanol sclerotherapy underwent follow-up imaging,
we did not evaluate the response after ethanol sclerother-
apy in 16 of the 87 patients. Clinical follow up was
performed for all the patients, and although the clinical
outcome of those 16 patients was not used for objective
analysis, we thought that the clinical outcome of these
patients could replace the therapeutic outcome.
In conclusion, ethanol sclerotherapy is an effective
treatment for CVMs, and it is wise to begin this treatment
as early as possible once a diagnosis is made. Careful
planning is essential to reduce the potential risks of this
procedure, and long-term follow up of patients is required
to detect any recurrence. 
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